Cargando…
Non‐small cell lung cancer with EGFR (L858R and E709X) and CNNB1 mutations responded to afatinib
Lung cancer with complex epidermal growth factor receptor (EGFR) and CTNNB1 comutations is rare, and the efficacy of tyrosine kinase inhibitors (TKIs) is generally poor. Here, we encountered a lung cancer patient with complex EGFR (L858R and E709X) and CTNNB1 comutations who successfully responded t...
Autores principales: | Kunishige, Michihiro, Ichihara, Seiya, Kadota, Naoki, Okano, Yoshio, Machida, Hisanori, Hatakeyama, Nobuo, Naruse, Keishi, Shinohara, Tsutomu, Takeuchi, Eiji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons Australia, Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891858/ https://www.ncbi.nlm.nih.gov/pubmed/36519636 http://dx.doi.org/10.1111/1759-7714.14775 |
Ejemplares similares
-
Late‐onset acute type 1 diabetes mellitus 7 months after discontinuation of pembrolizumab against lung cancer
por: Ichihara, Seiya, et al.
Publicado: (2022) -
A single dose of pembrolizumab treatment causing a profound and durable response in lung cancer
por: Kondo, Yoshihiro, et al.
Publicado: (2022) -
Pretreatment eosinophil counts as a predictive biomarker in non‐small cell lung cancer patients treated with immune checkpoint inhibitors
por: Takeuchi, Eiji, et al.
Publicado: (2023) -
Dramatic response to immunochemotherapy followed by salvage surgery in an elderly lung cancer patient
por: Okano, Yoshio, et al.
Publicado: (2021) -
Complete and durable response of pulmonary large‐cell neuroendocrine carcinoma to pembrolizumab
por: Kadota, Naoki, et al.
Publicado: (2021)